Gyre COO exercises options and sells 11,000 shares
GYRE THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a series of option exercises paired with open-market sales of common stock. On June 9, 10, and 18, he exercised stock options at $0.75 per share to acquire a total of 11,000 shares of common stock, then sold 11,000 shares in open-market transactions at prices reported around $6.15–$6.35 per share. A footnote states some sales were reported as a weighted average with individual trades between $6.20 and $6.30 per share. After these transactions, Ye directly holds 700,000 shares of Gyre Therapeutics common stock.
Insider Trade Summary
Exercise and Sale: 11,000 shares ($60K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Ye Weiguo
Role
Chief Operating Officer
Sold
11,000 shs ($69K)
Approx. gross sale proceeds
$69K
Approx. exercise cost
$8K
Approx. pre-tax spread
$60K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,000 | $0.75 | $2K |
| Sale | Common Stock | 3,000 | $6.35 | $19K |
| Exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,000 | $0.75 | $4K |
| Sale | Common Stock | 5,000 | $6.24 | $31K |
| Exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,000 | $0.75 | $2K |
| Sale | Common Stock | 3,000 | $6.15 | $18K |
Holdings After Transaction:
Stock Option (Right to Buy) — 827,701 contracts (Direct);
Common Stock — 700,000 shares (Direct)
Footnotes (2)
- F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F2. These options are vested in full.
Key Figures
Shares sold: 11,000 shares
Shares acquired via exercise: 11,000 shares
Sale prices: $6.15, $6.24, $6.35 per share
+4 more
7 metrics
Shares sold
11,000 shares
Total common stock sold in open-market transactions on June 9–18, 2026
Shares acquired via exercise
11,000 shares
Common stock acquired by exercising stock options at $0.75 per share
Sale prices
$6.15, $6.24, $6.35 per share
Per-share prices for common stock sales on June 9, 10 and 18, 2026
Weighted average sale range
$6.20–$6.30 per share
Range of prices underlying weighted average sale disclosure in footnote
Option exercise price
$0.75 per share
Conversion or exercise price for stock options exercised into common stock
Shares held after transactions
700,000 shares
Direct common stock ownership following June 2026 transactions
Option expiration
October 31, 2030
Expiration date shown for the exercised stock options
Key Terms
open-market sale, Stock Option (Right to Buy), derivative security, weighted average sale price, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sale price financial
"The price reported represents the weighted average sale price per share."
vested in full financial
"These options are vested in full."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did GYRE COO Weiguo Ye report?
Weiguo Ye reported exercising stock options to acquire 11,000 GYRE common shares at $0.75 each, then selling 11,000 shares in open-market trades at prices around $6.15–$6.35 per share, according to the Form 4 transactions dated June 9–18, 2026.
At what prices did GYRE COO Weiguo Ye sell common stock?
The Form 4 shows sales of GYRE common stock at per-share prices of $6.15, $6.24, and $6.35. A footnote adds that certain shares were sold at weighted average prices between $6.20 and $6.30, across multiple individual transactions.
What stock options did the GYRE COO exercise in this filing?
Weiguo Ye exercised options covering 11,000 shares of GYRE common stock with a conversion or exercise price of $0.75 per share. The derivative entries describe “Stock Option (Right to Buy)” securities and note that the options referenced are vested in full.
Were the GYRE insider stock sales reported as weighted average prices?
Yes. A footnote explains that one set of GYRE stock sales is reported using a weighted average sale price per share, with actual trade prices ranging from $6.20 to $6.30. The COO offers to provide full trade details upon request to specified parties.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates